Abivax Publishes 2025 Financial Calendar
PARIS, France – January 28, 2025 – 8:30 AM CET
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar.
Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press Release Universal Registration Document (Euronext) Annual Report on Form 20-F
Monday, June 2, 2025 (after US Market closes) 2025 Q1 Financial Results (as of March 31, 2025) Press Release Report on Form 6-K
Friday, June 6, 2025 2025 Annual General Meeting (AGM) Live meeting in Paris, France
Monday, August 11, 2025 (after US Market closes) 2025 Half-Year Business and Financial Report (as of June 30, 2025) Press Release Half-Year Financial Report (Euronext) Report on Form 6-K
Monday, December 15, 2025 (after US Market closes) 2025 Q3 Financial Results (as of September 30, 2025) Press Release Report on Form 6-K
About Abivax: Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Abivax’s focus on developing therapies for chronic inflammatory diseases has the potential to revolutionize the treatment of such conditions. By harnessing the body’s natural regulatory mechanisms, Abivax aims to provide innovative therapies that can effectively stabilize the immune response in patients, leading to improved outcomes and better quality of life.
Chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis, can have a significant impact on patients’ daily lives, causing pain, discomfort, and potentially severe complications. Traditional treatments for these conditions often come with side effects and may not always provide long-term relief. Abivax’s approach offers a promising new avenue for addressing these diseases and improving the lives of patients.
Impact on Individuals:
For individuals living with chronic inflammatory diseases, the development of innovative therapies by Abivax could offer hope for better management of their condition. By stabilizing the immune response, these therapies have the potential to reduce symptoms, prevent flare-ups, and improve overall quality of life for patients.
Impact on the World:
On a larger scale, the work of Abivax in developing therapies for chronic inflammatory diseases could have far-reaching implications for the healthcare industry and society as a whole. By providing more effective and targeted treatments for these conditions, Abivax has the potential to reduce the burden on healthcare systems, improve patient outcomes, and contribute to overall public health and well-being.
Conclusion:
Abivax’s publication of its 2025 financial calendar marks an important step in its mission to develop innovative therapies for chronic inflammatory diseases. With a focus on harnessing the body’s natural regulatory mechanisms, Abivax is paving the way for a new era of treatment options that could significantly benefit patients and society as a whole. The potential impact of Abivax’s work extends beyond individual patients to the healthcare industry and public health, offering hope for a brighter future in the treatment of chronic inflammatory diseases.
